A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

This randomised multicentre phase II study was conducted to investigate the activity and safety of two oral fluoropyrimidines, capecitabine or S-1, in elderly patients with advanced gastric cancer (AGC). Elderly (⩾65 years) chemo-naive patients with AGC were randomly assigned to receive capecitabine...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, J-L, Kang, Y-K, Kang, H J, Lee, K-H, Zang, D Y, Ryoo, B-Y, Kim, J G, Park, S R, Kang, W K, Shin, D B, Ryu, M-H, Chang, H M, Kim, T-W, Baek, J H, Min, Y J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527839/
https://www.ncbi.nlm.nih.gov/pubmed/18665164
http://dx.doi.org/10.1038/sj.bjc.6604536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527839/
https://www.ncbi.nlm.nih.gov/pubmed/18665164
http://dx.doi.org/10.1038/sj.bjc.6604536

Ejemplares similares